Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors (eculizumab/ravulizumab) control intravascular hemolysis but do not prevent residual extravascular hemolysis. The newly approved complement inhibitor, pegc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Raymond S. M., Pullon, Humphrey W. H., Amine, Ismail, Bogdanovic, Andrija, Deschatelets, Pascal, Francois, Cedric G., Ignatova, Kalina, Issaragrisil, Surapol, Niparuck, Pimjai, Numbenjapon, Tontanai, Roman, Eloy, Sathar, Jameela, Xu, Raymond, Al-Adhami, Mohammed, Tan, Lisa, Tse, Eric, Grossi, Federico V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375762/
https://www.ncbi.nlm.nih.gov/pubmed/35869170
http://dx.doi.org/10.1007/s00277-022-04903-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375762/
https://www.ncbi.nlm.nih.gov/pubmed/35869170
http://dx.doi.org/10.1007/s00277-022-04903-x

Ejemplares similares